A5078754611- Allergic Rhinitis and Sensitization
- Food Allergy and Anaphylaxis Research
- Asthma and respiratory diseases
- Transgenic Plants and Applications
- Dermatology and Skin Diseases
- Monoclonal and Polyclonal Antibodies Research
- Vaccine Coverage and Hesitancy
- Extracellular vesicles in disease
- Inhalation and Respiratory Drug Delivery
- Pharmaceutical studies and practices
- RNA Interference and Gene Delivery
- Immunotherapy and Immune Responses
- Occupational exposure and asthma
- Contact Dermatitis and Allergies
Cégep de Lévis
2024
American Academy of Allergy, Asthma and Immunology
2016
The sublingual mucosa has been used for many years to apply allergenic extracts the purpose of specific immunotherapy (IT). Although IT (SLIT) is both safe and efficacious, density antigen-presenting cells higher in other regions oral cavity vestibule, which make them a potentially desirable target IT.To present concept mucosal (OMIT) provide pilot data this extended application SLIT.An open-label, 12-month, prospective study was undertaken as preliminary step before full-scale clinical...
Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it poorly developed compared to symptomatic drugs. The main reasons come from duration implying monthly injections during 3 5 years or daily sublingual use, and risk of allergic side-effects. To become a more attractive alternative lifelong drug improvements AIT are needed. Among most promising new strategies use bioparticles presentation target antigen immune system as they...
To the Editor, Allergen immunotherapy (AIT) is only disease-modifying treatment for allergic diseases with proven sustained efficacy, but long duration, chronic exposure to aluminium salts and side-effects are major drawbacks. AIT aims redirect underlying T helper type 2 (Th2)-skewed immune response towards an allergen-specific mixed 1 (Th1)/regulatory cell (Treg) response.1 Recently, plant-made enveloped eBioparticles (eBPs) were introduced as allergen expression platform display...
As the only market-authorized allergen immunotherapy (AIT) for peanut allergy is accompanied by a high risk of side effects and mainly induces robust desensitization without sustained efficacy, novel treatment options are required. Peanut-specific plant-derived eBioparticles (eBPs) surface expressing Ara h 2 at density have been shown to be very hypoallergenic. Here, we assessed dendritic cell (DC)-activating T polarization capacity these peanut-specific eBPs.Route kinetics eBP uptake were...
Was America sleeping on its laurels or just snubbing molecular allergology / component-resolved diagnosis? The clinical implementation of testing in Europe dates back to the early 2000's. Although importance major allergens seems have been readily recognized by allergy professionals North America, more exhaustive exploration and use is still waiting. In this day age instant communication worldwide professional collaboration, it surprising that such a gap could developed. A review factors may...
This article was originally published online on 03 February 2014 While it has been used clinically in Europe since the early 2000, molecular allergology remains relatively unknown to a number of clinicians involved field allergy and this at time when understanding level proteins allows for novel diagnostic therapeutic avenues. Molecular offers better dynamics certain patients, particularly some situations food multi-allergy contexts. A introduction science allergology, based 6 concepts...
Current allergen products carry significant limits in terms of their quality and consistency this likely accounts for shortcomings the clinical diagnosis allergy its treatment through desensitization. Increasingly, stakeholders (clinicians, pharmaceutical industry regulatory agencies) are seeking better, more effective aligned with principles Precision Medicine.